Delta Variant Surges in Colorado as the Bands Play on ksut.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksut.org Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
CAMBRIDGE, Mass., July 15, 2021 /PRNewswire/ PAQ Therapeutics, a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, today announced the completion of its $30 million Series A financing. PAQ s approach and technology expands the therapeutic potential of autophagy - the body s most versatile mechanism for natural cellular degradation – to target not only disease-causing proteins but lipids, pathogens and other substrates with the goal of restoring health. Sherpa Healthcare Partners led the Series A financing with participation from Huagai Capital, MSA Capital, and MRL Ventures Fund, joined by seed investors, Nest.Bio Ventures and Matrix Partners China.
Urgent action is necessary to stop the US Delta variant surge!
The United States is in the midst of a major new upsurge of the COVID-19 pandemic that has already taken the lives of 624,000 people. Over the past month, daily cases have increased 250 percent, driving a rise in hospitalizations and a significant increase in the daily death rate.
“The Delta (4th) wave in the United States is already showing it to be on a path to its the worst yet” in major hotspots, noted Eric Topol, a professor of molecular medicine at the Scripps Research Institution. The surge is concentrated in the poorest sections of the country, including Arkansas, Mississippi, Missouri, Florida and Nevada, where vaccination rates are lowest. In Missouri, the tenth-poorest state in the country which has one of the lowest vaccination rates, hospitals are at the highest occupancy at any point of the pandemic. “We only get beds available when someone dies, which happens several times a day,” Terrence Coult
Invitations are sent via the Eboks secure digital mail system.
Digital Health News ~ Cora Lydon ~ 15/07/2021
The acquisition will bring together Induction Healthcare’s virtual care platform with Attend Anywhere’s solution, which is used by 90% of NHS trusts across the UK.
Healthcare IT News ~ Kat Jercich ~ 15/07/2021
The Office of the National Coordinator for Health IT announced this week that the Trusted Exchange Framework and Common Agreement, or TEFCA, will be live in 2022.
MedCity News ~ Elise Reuter ~ 15/07/2021
It plans to offer Teladoc’s virtual care platform for hospitals through its video conferencing software, Microsoft Teams.
Healthcare Info Security ~ Marianne Kolbasuk McGee ~ 15/07/2021
ADVERTISEMENT
Novartis Expert Accuses Rival s Atty Of Gaslighting In IP Trial
Law360, Oakland, Calif. (July 15, 2021, 10:02 PM EDT) A chemist hired by Novartis testified that a Daiichi Sankyo subsidiary s skin cancer treatment patents are invalid as either obvious or too vague, accusing opposing counsel of gaslighting him during a contentious examination in a California federal jury trial on Thursday.
Scripps Research Institute professor Dr. Phil S. Baran took the stand during the fourth day of an in-person jury trial that kicked off Monday over Plexxikon s claims that Novartis owes royalties for selling a drug called Tafinlar that allegedly infringes two patents.